arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

MoonLake Immunotherapeutics

MLTX

$12.92 ▼ -0.45 (-3.37%) at close

6 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

MoonLake Immunotherapeutics faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $832.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -64.8% ↘

FCF / Share $-3.04 ↘

Trailing P/E —

Price / Book 2.7x

FCF Yield —

Debt / Equity 0.24

info Valuation on last close. End-of-day price, Sep 23, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-227.32M

↓ -91.1% —

FCF / Share Free cash flow per share

$-3.04

↓ -63.3% —

Long-Term Debt Long-term obligations

$74.10M

— —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
EPS Growth YoY (%)	-86.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-158.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	57.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-91.1% Weak ↑ Weak Improving Year-over-year change in net income	-230.3% Weak ↑ Weak Improving Year-over-year change in net income	27.9% Excellent Excellent Year-over-year change in net income	-1000.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-63.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	-112.5% Weak Weak Year-over-year change in free cash flow	54.0% Excellent Excellent Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Effective Tax Rate (%) (%)	-0.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	0.86x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.20x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.12x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.13x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-64.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-32.1% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-10.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-133.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	51.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-57.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-29.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-10.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-84.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-3.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-74.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-598%)	-26.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-277%)	-7.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-148%)	-102.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-781%)	64.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+329%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Debt to Equity (x)	0.24x Excellent → Excellent Stable Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-59%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—
Interest Coverage (x)	-48.40x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—
Net Debt (USD)	$-260.42M	$-180.43M	$-451.17M	$-39.51M	$-666.79K	$-1.34M
Debt / EBITDA (x)	-0.31x Excellent → Excellent Stable Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-3.53	$-1.89	$-0.73	$-1.70	—	—
Free Cash Flow per Share (USD)	$-3.04	$-1.86	$-0.88	$-1.90	—	—
Book Value per Share (USD)	$4.72	$7.11	$10.09	$1.67	—	—
Tangible Book Value per Share (USD)	$4.72	$7.11	$10.09	$1.67	—	—
Basic Weighted Avg Shares (shares)	64.46M	62.87M	49.12M	29.36M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$376.22M	$451.83M	$504.20M	$68.85M	$-3.08M	$1.49M
LT Debt (USD)	$74.10M	$0.00	—	—	—	—
Total Equity (USD)	$304.48M	$446.82M	$495.68M	$48.90M	$-7.06M	$-2.52M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Depreciation Expense (USD)	$2.62M	$1.39M	$370.32K	$12.36K	—	—
Net Income, GAAP (USD)	$-227.32M	$-118.94M	$-36.01M	$-49.97M	$-4.54M	—
Operating Cash Flow (USD)	$-196.01M	$-116.59M	$-42.78M	$-55.89M	$-611.07K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 24 quarters

MoonLake Immunotherapeutics

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MLTX with peers